1 / 34

Point Prevalence Survey of Hospital-Acquired Infections & Antimicrobial Use in Ireland

Point Prevalence Survey of Hospital-Acquired Infections & Antimicrobial Use in Ireland. PPS Data Collector Training April 2012 Antimicrobial Use & Case Studies Presentation 4. Acknowledgements – Case Studies. Ms Siobhan Barrett – Antimicrobial Pharmacist

sumana
Download Presentation

Point Prevalence Survey of Hospital-Acquired Infections & Antimicrobial Use in Ireland

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Point Prevalence Survey of Hospital-Acquired Infections & Antimicrobial Use in Ireland PPS Data Collector Training April 2012 Antimicrobial Use & Case Studies Presentation 4

  2. Acknowledgements – Case Studies • Ms Siobhan Barrett – Antimicrobial Pharmacist • Dr Sarah Bergin – Specialist Registrar, Microbiology • Dr Caroline Fielding – Specialist Registrar, Microbiology • All cases are fictional

  3. Antimicrobial Use • Prescription of antibacterials and/or antifungals via systemic route • Systemic route: • Parenteral: intravenous (IV) or intramuscular (IM) • Enteral: oral (PO), rectal (PR), per NG/NJ tube • Inhalation: nebulised • This PPS is not collecting data on: • Antiviral use • Treatment of tuberculosis • Topical antimicrobial use

  4. Antimicrobial Use • Record all systemic antimicrobials prescribed at time of the survey: • Treatment of infection • Medical prophylaxis • Other indication – erythromycin for prokinetic use or azithromycin for anti-inflammatory use • Record planned intermittent antimicrobial use • Three times weekly medical prophylaxis • Haemodialysis patient receiving antimicrobial treatment at haemodialysis sessions – 3/week or alternate days • Patient with renal failure receiving alternate day treatment

  5. Antimicrobial Use • Record surgical prophylaxis prescribed between 8am on day before survey and 8am on day of survey – 24 hour period • Do not record surgical prophylaxis newly prescribed after 8am on day of survey • This section on antimicrobial use aims to find out clinician’s reason for prescribing the antimicrobial based on available information on date agent prescribed • You are NOT being asked to decide if the prescribing is appropriate

  6. Patient Form (Form C) – Section 4Antimicrobial Use

  7. Form C: Section 4 • Antimicrobials are coded by their generic name AND accompanying ATC5 code • See Appendix A – Table 4 for generic names and accompanying ATC5 codes • Top ten agents used listed first • Alphabetical thereafter • Note some agents have a different ATC5 code depending on route of administration: • Metronidazole enteral (e.g. PO/PR) = P01AB01 • Metronidazole parenteral (IV) = J01XD01 • Also vancomycin enteral vs parenteral

  8. Appendix A – Table 4

  9. Form C: Section 4 • There is space to record up to five separate antimicrobial prescriptions • Antimicrobials 1 & 2 on page 1 • Antimicrobials 3, 4, & 5 on page 3/extension sheet • Record the generic name and ATC5 code • Record the route of administration

  10. Form C: Section 4 • ‘Reason recorded in notes’: • Check the notes/medication chart to see if prescriber recorded reason for prescription at the time of prescribing: ‘Yes’ or ‘No’ • ‘Unknown’ option should only be used if notes/medication chart unavailable for review

  11. Indication for antimicrobial use • There are TEN options for indication • Treatment of infection: • Community-acquired infection = CI • Long-term care facility/nursing home-acquired infection = LI • Hospital-acquired infection = HI • Surgical prophylaxis: • SP1 – Single dose prescribed one dose only • SP2 – >1 dose but <24 hours total • SP3 – Prescribed for >24 hours

  12. Indication for antimicrobial use • There are TEN options for indication: • Medical prophylaxis – e.g. co-trimoxazole prophylaxis against pneumocystis pneumonia, penicillin administered during labour to woman known to be colonised with beta haemolytic streptococcus Group B a.k.a Group B Strep = MP • Other indication – e.g. Erythromycin used as pro-kinetic, azithromycin used as anti-inflammatory = O • Unknown indication = UI – indication not recorded in notes • Unknown = UNK – Indication could not be verified as notes missing/unavailable • When recording indication – use the indication code

  13. Diagnosis site codeSee Appendix A – Table 5 • Diagnosis site = Prescribing clinician’s opinion regarding likely site of infection • Diagnosis site is ONLY recorded when the indication for antimicrobial use is treatment intention for infection • If indication is prophylaxis (MP or SP) or ‘other’ reason – record NA – not applicable as diagnosis site code • Diagnosis site code list differs to the HAI case definition list: • Clinician may be treating infection which is CI or LI • Clinician is using clinical judgement • You are using surveillance definitions for HAI • It is not the objective of the PPS to relate use of antimicrobials to HAI

  14. Prescriber’s diagnosis site code listAppendix A

  15. Prescriber’s diagnosis site code listAppendix A

  16. Meets local policy • Prescription meets local prescribing policy for: • Empirical treatment of infection • Surgical prophylaxis • Prescription has been rationalised based on latest microbiology results • Answers are ‘Yes’, ‘No’, ‘Not assessable’ • ‘Unknown’ option should only be selected if patient’s notes are not available for review • Assess compliance with local policy based on choiceof agent only– dose, frequency, duration, route are not factors in assessing compliance

  17. Meets local policy • Prescription can only be assessed against local policy where a policy exists – if there is no local policy for that clinical scenario: prescription is not assessable • Prescription can only be assessed against local policy if the reason for prescription can be determined from review of patient’s notes and/or discussion with staff caring for the patient – If reason cannot be determined: prescription is not assessable • If patient has an antimicrobial allergy preventing compliance with local policy: prescription is not assessable • If prescription advised specifically by infection expert: not assessable against local policy

  18. Protocol page 36: Figure 11

  19. Form C: Section 4 – Case Studies

  20. Case A • Bradley Pitt, 62 year-old male, previously healthy • Admitted to ENT ward this hospital 25/4/12 under care of maxillofacial surgeon • Resection mandibular tumour and bilateral neck dissection since admission • PPS date 21/5/12 • Prescribed metronidazole 400mg tds via nasogastric tube since 18/5/12 • Notes reviewed: On 18/5 NCHD wrote ‘Diarrhoea since yesterday, send stool, start metronidazole’ • 19/5/12 – Clostridium difficile toxin detected in faeces • Metronidazole is treatment of choice for CDI in hospital policy

  21. Case A – Form C: Section 4

  22. Case B • Grace Monroe, 56 year-old lady • Admitted to this hospital via ED from home 28/4/12 • CABG and mitral valve repair performed in another hospital 6/4/12 • Presents with chest pain, sternal wound oozing pus and painful venous graft wound on lower leg • Blood cultures and wound swabs taken

  23. Case B • Admitted to general medical ward under cardiology • Commenced on IV vancomycin 1gm bd and gentamicin 80mg/kg tds • PPS date 08/05/12 • Notes reviewed: 28/4 - ‘Discussed with microbiology, cover for possible endocarditis and wound infection’ • Blood cultures and wound swab – sterile • Transoesophageal echocardiogram 01/05 – suspicious vegetation on mitral valve • Continues on therapy as prescribed

  24. Case B - Form C: Section 4 x

  25. Case C • Angela Jolly, 84 year-old female • Admitted from nursing home to this hospital 16/4/12 via ED • Reviewed by PPS team 15/5/12 • Prescribed coamoxiclav 625mg tds po since 13/5/12 • Notes reviewed: 13/5 ‘febrile, suprapubic pain, note MSU 10/5 Proteus mirabilis – sensitive to augmentin. Suspect UTI – Start augmentin’ • Hospital does not have a policy for empiric treatment of hospital-acquired infection

  26. Case C – Form C: Section 4

  27. Case D • Thomas Cruise, 76 year old male • Transferred from elective orthopaedic hospital under orthopaedic consultant to coronary care unit in this hospital 08/03/12 having had left total hip replacement 25/02/12 • Transferred for medical management as he developed pneumonia, sepsis with acute kidney injury and acute coronary syndrome eight days post-op • Slow improvement and rehabilitation • Transferred out to orthopaedic ward 31/3/12

  28. Case D • Haemodialysis dependent • Dialysed three times weekly via permcath • MRSA detected on nasal swab 04/05/12 • Commenced mupirocin nasal ointment 05/05/12 • Deteriorated acutely 05/05/12 with dyspnoea, productive cough and new CXR infiltrate • Commenced empirically on piperacillin/tazobactam and vancomycin 1gm 05/05 for suspected healthcare associated pneumonia as documented by medical registrar on-call following discussion with consultant microbiologist • Vancomycin dosed as per levels in haemodialysis – given 07/05 • PPS team arrive on ward 08/05/12

  29. Case D – Form C: Section 4

  30. Case E • Georgina O’Clooney, 66 year-old lady • Admitted via ED 02/05/12 directly to ICU • Haematology outpatient – aplastic anaemia • Presented with febrile neutropenia, bilateral pulmonary infiltrates on CXR, hypoxia and hypotension – commenced on empiric piperacillin/tazobactam, vancomycin and clarithromycin • Intubated, CVC inserted, urethral catheter inserted • PPS team arrive to ICU 08/05/12

  31. Case E • Daily microbiology ICU round notes reviewed – no positive microbiology to date • Severe community acquired pneumonia – not responding to initial empiric therapy • Prescribed – Meropenem 1gm tds IV (D2), linezolid 600mg bd via NG tube 9 (D3), clarithromycin 500mg bd via NG tube (D7), cotrimoxazole 960g via NG tube alternate days since admission & oseltamivir 150mg bd via NG tube (D4)

  32. Case E – Form C: Section 4

  33. Case E – Form C: Section 4

  34. Any Questions? pps2012@hpsc.ie

More Related